NCT03836222View on ClinicalTrials.gov

Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

June 4, 2018

Study Completion Date

June 4, 2018

Conditions
Healthy
Interventions
DRUG

PCS499

MR tablet

DRUG

Trental

comparator tablet

Trial Locations (1)

Unknown

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Processa Pharmaceuticals

INDUSTRY

NCT03836222 - Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects | Biotech Hunter | Biotech Hunter